Destiny USA owner, Pyramid Management Group, defaults on loans owed for Buffalo-area mall
BUFFALO, N.Y. (WSYR-TV) — Syracuse-based Pyramid Management Group, the owner of Destiny USA, has defaulted on a multi-million-dollar loan related to its Walden Galleria mall outside of Buffalo.
The lenders filed a lawsuit against Pyramid Management Group in Erie County State Supreme Court on Thursday to initiate the mortgage foreclosure process.
The company owed more than $230 million as of April 2022.
In May, Pyramid CEO Stephen Congel told Buffalo Business First that he was optimistic about his team's negotiations with the lenders.
In early May, representatives for the lenders sent a letter to Pyramid Management Group demanding 'immediate payment in full of the matured indebtedness.'
By failing to pay, the letter states, the mall's current owners risk losing rights to manage the property or foreclosure, among other penalties.
Spinoso Real Estate Group, also Syracuse-based, has applied to take over management of Walden Galleria as a court-approved receiver.
Spinoso took over management of Pyramid's foreclosed Palisades Center near New York City last year. The company lost Champlain Center in Plattsburgh, Hampshire Mall in Massachusetts and Aviation Mall near Lake George.
Many worry Destiny USA could be next.
Last August, NewsChannel 9 reported Destiny USA was threatened with 'enforcement action' for Pyramid's inability to pay back $430 million in debt for the construction of the mall and its expansion.
In a statement last year, the CEO of Pyramid Management Group, Stephen Congel, said, 'We are currently engaged with the special servicer regarding modification of the loan and will continue to provide an exceptional experience for our 17 million annual guests and employees.'
Pyramid Management Group has not responded to NewsChannel 9's request for comment related to the pending foreclosure of Walden Galleria.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS, June 4, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact:Avant Technologies, Inc. info@ View original content to download multimedia: SOURCE Avant Technologies Inc.
Yahoo
33 minutes ago
- Yahoo
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /CNW/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis—this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Jen Jen Yeh, MD, a surgical oncologist and professor at UNC-Chapel Hill with joint appointments in Surgery and Pharmacology. She serves as assistant dean of translational research in UNC School of Medicine and associate director of translational research in UNC Lineberger Comprehensive Cancer Center. Dr. Yeh is widely recognized for her expertise in pancreatic cancer and translational oncology. Joseph DeSimone, PhD, an award-winning chemist, entrepreneur, and academic, currently serving as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He is globally known for his breakthroughs in materials science, nanomedicine, and advanced manufacturing, including 3D printing. Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers, Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity BiosciencesContinuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex About Focal MedicalFocal Medical, Inc. develops energy-based chemotherapy delivery systems that enable direct application of drugs to tumor sites. Its mission is to improve efficacy and reduce toxicity in the treatment of solid tumors, with an initial focus on pancreatic View original content to download multimedia: SOURCE Continuity Biosciences LLC View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
33 minutes ago
- Associated Press
Ford recalls nearly half a million 2016-17 Explorers due to door trim that can detach while driving
WASHINGTON (AP) — Ford is recalling nearly half a million older Explorer models because part of the door trim can detach while driving and cause a dangerous road hazard, U.S. auto safety regulators said Wednesday. A notice posted by the National Highway Traffic Safety Administration said the recall covers 492,145 Ford Explorers, model years 2016-2017. The vehicles were produced between June 11, 2015 and April 19, 2017. Ford Motor Co. first recognized the problem as far back as 2019, but did not consider it an 'unreasonable risk to safety,' the NHTSA report said. In March of this year, the NHTSA shared with Ford dozens of vehicle owner reports of the problem, leading Ford to further investigate it, eventually leading to the recall. Ford concluded that lack of proper adhesion was causing the trim to loosen, adding that it is unaware of accidents or injuries related to the defect. The Dearborn, Michigan-based automaker expects to start sending notification letters to owners on June 9. When a remedy to fix the faulty part has been determined, owners will be notified by mail and instructed to take their vehicles into a Ford or Lincoln dealership to have the trim fixed at no cost. The NHTSA recall number is 25V347. The manufacturer's recall number is 25S53.
